Stay updated with breaking news from Bio Rad Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A number of firms have modified their ratings and price targets on shares of Bio-Rad Laboratories (NYSE: BIO) recently: 5/4/2022 – Bio-Rad Laboratories was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $526.00 price target on the stock. According to Zacks, “Bio-Rad exited the […]
Bio-Rad Laboratories (NYSE:BIO – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports. The brokerage presently has a $576.00 price objective on the medical research company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of […]